A more recent addition to my transformational technologies portfolio, Medarex (NASDAQ:MEDX), has scored a huge win. The company, along with Massachusetts Biologic Laboratory, will get $60 million upfront from Merck (NYSE:MRK) for license rights to a monoclonal antibody that apparently cures C. difficile infection. They are eligible for another $165 million in milestones as well as royalties.

The pig flu is scaring the wits out of travelers across the globe. While a handful of companies are enjoying surging share prices today, the biggest winners will be the news networks that are blowing the whole thing out of proportion.